Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
Lviv Regional State Clinical Treatment Endocrinological Center, Lviv, Ukraine.
Endocr Regul. 2021 Dec 7;55(4):224-233. doi: 10.2478/enr-2021-0024.
Significantly underdiagnosed, diabetes-associated cardiac autonomic neuropathy (CAN) causes a wide range of cardiac disorders that may cause life-threatening outcomes. This study investigated the effects of alpha-lipoic acid (ALA) on arterial stiffness and insulin resistance (IR) parameters in type 2 diabetes mellitus (T2D) patients and definite CAN. A total of 36 patients with T2D and a definite stage of CAN were recruited. This investigation was carried out on two separate arms: traditional hypoglycemic therapy (n=18, control) and ALA (n=18) 600 mg in film-coated tablets/q.d. in addition to traditional hypoglycemic therapy. The duration of the study was three months. In subjects with T2D and definite stage of СAN, treatment with ALA resulted in a significant decrease of glucose, immunoreactive insulin concentration, and Homeostasis Model Assessment (HOMA)-IR (HOMA-IR) parameters; pulse wave velocity (PWV), aorta augmentation index (AIxao) during the active period of the day and decrease of PWV, AIxao, and brachial augmentation index during the passive period of the day compared with the results, obtained in the control group. Therefore, the administration of ALA to patients with T2D for three months promotes the improvement of glucose metabolism and arterial stiffness parameters. In patients with T2D and definite stage of СAN treatment with ALA improved HOMA-IR and arterial stiffness parameters. These findings can be of clinical significance for the complex treatment of diabetes-associated CAN.
糖尿病相关心脏自主神经病变(CAN)的诊断严重不足,可导致多种心脏疾病,从而危及生命。本研究探讨了α-硫辛酸(ALA)对 2 型糖尿病(T2D)患者和明确的 CAN 患者动脉僵硬和胰岛素抵抗(IR)参数的影响。共招募了 36 名 T2D 合并明确 CAN 患者。本研究分为两个独立的组别进行:传统降糖治疗(n=18,对照组)和 ALA(n=18)600mg 薄膜包衣片/天,联合传统降糖治疗。研究持续时间为三个月。在 T2D 合并明确 CAN 的患者中,ALA 治疗可显著降低血糖、免疫反应性胰岛素浓度和稳态模型评估(HOMA)-IR(HOMA-IR)参数;日间活动期的脉搏波速度(PWV)、主动脉增强指数(AIxao)以及日间被动期的 PWV、AIxao 和肱动脉增强指数均降低。与对照组相比,结果均有显著改善。因此,ALA 治疗 T2D 患者三个月可改善血糖代谢和动脉僵硬参数。在 T2D 合并明确 CAN 的患者中,ALA 治疗可改善 HOMA-IR 和动脉僵硬参数。这些发现对糖尿病相关 CAN 的综合治疗具有临床意义。